XBI: Big Pharma Can Keep The 76% Rally Going

State Street SPDR S&P Biotech ETF (XBI) is rated Buy, with 8%-14% total return expected over 6-12 months despite a 76% prior-year rally.

XBI's modified equal-weight structure offers broad exposure to over 150 biotech names, benefiting from ongoing M&A and improved capital access.

Recent large-cap pharma acquisitions and selective capital flows support XBI's thesis, though volatility remains high and returns are likely to moderate.

Risks include tightening financing, slowing M&A, and underperformance of smaller biotech; IBB outperformance would warrant caution on XBI's volatility.

The State Street SPDR S&P Biotech ETF ( XBI ) has returned 75.75% over the past year, which would normally make me cautious about chasing another leg higher.